Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro
Six months of adjuvant nivolumab plus ipilimumab after nephrectomy for renal cell carcinoma offers no disease-free survival benefit, reveals trial that highlights treatment duration and tolerability.
Medscape Medical News
source https://www.medscape.com/viewarticle/980547?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/980547?src=rss
Comments
Post a Comment